Kevin Payne — Addressed by name as the senator asking about natural versus synthetic psilocybin.
John Kavanagh — Identified as supportive of the bills brought forward.
John Kavanagh — John Kavanagh asked whether the experience of confronting repressed thoughts comes from the drug itself or from accompanying therapeutic support, specifically whether a psychologist, psychiatrist, or therapist needs to be present during the drug experience to help bring those thoughts out.
John Kavanagh — A senator’s question about the treatment focused on the clinical process and dosage, and the discussion continued with follow-up reference to concerns about who opposes the treatment.
John Kavanagh — Senator John Kavanagh speaks after the witness testimony, asking a question and continuing the same exchange; a later transcript reference appears to misrender his name but is part of the same discussion.
Flavio Bravo — Identified as supportive of the bills brought forward.
Alan Mullen — Alan Mullen, a retired U.S. Army Special Forces Master Sergeant, testifies about his military service and the challenges many combat veterans face with PTSD, traumatic brain injury, and ineffective conventional treatments. He explains how he came to participate in a Stanford ibogaine study and describes the treatment process in detail: preparatory sessions with therapists, counselors, and coaches; the monitored 12- to 15-hour administration with medical staff and cardiac monitoring; and the highly individual psychoactive experience, which for him involved confronting traumatic memories and grief while another participant reacted differently. He also contrasts ibogaine with the common escalation of painkillers, alcohol, and other drugs among veterans, notes that ibogaine is a natural plant-derived substance with roots in African ceremony, and concludes that the treatment could have significant implications for veterans, public health, and the future of mental health care, offering to answer further questions.
Kevin Payne — Senator Kevin Payne is referenced as someone the speaker has been discussing the issue with for years and as someone who has already worked on the issue, indicating his ongoing involvement and prior efforts on the matter.
Kevin Payne — Asked how ibogaine is pronounced and whether it is natural or manmade.
Kevin Payne — Senator Payne was invited to ask questions, briefly deferred to the speaker, and then thanked the chair as the exchange moved forward.
Kevin Payne — Senator Payne is called on to finish questions and continues his turn by asking about suicide, including whether there are any suicide numbers and whether VA data may undercount deaths, with the discussion also touching on PTSD.
Kevin Payne — Senator Payne discussed treatment options for mental health and suicide prevention, asking what therapies are legally available or recommendable, then comparing the high cost and repeated-session burden of ketamine with psilocybin-based approaches that may require fewer sessions. He noted he is running a bill to extend the referenced act and argued that successful research could lower costs and help more people, especially by improving outcomes for public safety personnel. The discussion also tied into the broader issue of suicide rates in the U.S.
Dr. Sue Cisley — Introduced as a familiar expert/witness.
JD — Mentioned in connection with a proper introduction; likely a pet or companion referenced by Dr. Cisley, but unclear.
Dan Freiburg — Introduced as President of the Professional Firefighters Association of Arizona.
Dr. Chang Trin — Introduced as a researcher.
J.D. Mesnard — Referenced as having commitments after the hearing; likely Senator J.D. Mesnard was not intended here, but the name 'Kavanaugh' is not in the member list and remains uncertain.
Sue Sisley — Sue Sisley introduced herself as the founder and principal investigator of Scottsdale Research Institute and described her background as an Arizona physician trained in internal medicine and psychiatry. She explained her long family practice experience with her mother in Phoenix and said she was initially skeptical about this area until she repeatedly heard similar stories from patients, especially veterans. She then noted that criminalization has made research extremely difficult, but emphasized that her team has continued persevering.
Dr. Hannah Sisley — Identified as Sue Sisley's mother and a family practice doctor who worked in Phoenix for 50 years.
Thomas Shope — Senator Shope is referenced twice in quick succession as having previously noted that these therapies are not taken home, reinforcing the same point without any change in topic.
Thomas Shope — Addressed as a committee member in the witness's opening remarks.
Thomas Shope — The speaker thanks Chairman Shope and the senators for the opportunity to speak, and later refers back to something Chairman Shope had already read earlier in the meeting.
Thomas Shope — Chairman Thomas Shope is addressed during a question-and-answer exchange, with the discussion continuing across two nearby mentions in the same general exchange.
Warren Petersen — Discussion about sending a letter from the Arizona legislature to President Trump asking for support of a right-to-try initiative, including a request that he urge the DEA to cooperate with the law or consider issuing an executive order.
Dr. Sue Sisley — Confirmed that the organization has several DEA Schedule I licenses, including one for manufacturing psilocybin mushrooms.
SRI — Discussed as the organization that may make psilocybin mushrooms available under Right to Try after phase one is complete.
Dr. Sue — Referenced in connection with explaining the clinical dosage and treatment process.
Dr. Sisley — Asked about opposition to the treatment approach and responded that groups like Drug-Free America are concerned.
Dan Freiberg — Dan Freiberg, president of the Professional Fire Fighters of Arizona, testified about the severe mental health crisis facing firefighters. He described suicides and crisis situations among long-serving firefighters, said the organization wants access to any treatment that is effective, safe, and vetted, and emphasized that firefighters are tired of losing colleagues. He explained that firefighters work far more hours than typical employees, face repeated traumatic exposures, and often lack built-in time off to pair with mental health treatment, unlike physical injuries. Freiberg illustrated the toll with examples from a drowning call and mandatory overtime, noting how such experiences affect focus, family life, and recovery. He concluded that firefighters need better solutions beyond traditional treatment alone and formally endorsed the effort on behalf of the 9,000 firefighters his organization represents.
Dan — The speaker thanks Dan and appears to be concluding his remarks before moving on to the next presenter.
Chung Trin — Chung Trin introduces himself as a mental health physician trained in psychedelic-assisted psychotherapy and describes his broader professional roles as a health care executive overseeing about 20,000 patients, a clinical trial research investigator, and an advocate for expanded mental health access. He then frames his testimony around FDA breakthrough therapy-designated treatments and the need for strategic policy actions in Arizona to ensure timely and safe patient access to FDA-approved psychedelic therapies.
Dr. Cicely — Dr. Cicely is referenced multiple times in a discussion about psychedelic and clinical research, with speakers noting her role in late-stage psychedelic research, her comments on the rigor of clinical studies, and her remarks in relation to current medications and related treatment considerations.
the doctor — A doctor’s research was referenced, and the speaker invited them to meet and discuss it further.